Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to its Form F-1 to update its prospectus and include information from its 2025 Form 20-F; no new securities are being registered. This amendment covers the resale of 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares issuable upon exercise of Series D warrants.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders; proceeds would go to those holders unless Series D warrants are exercised for cash. Each Depositary Share represents 100,000 Ordinary Shares. Ordinary Shares outstanding were 324,156,808,922 as of March 12, 2026.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to a Form F-1 to update its resale prospectus. The registration covers an aggregate of 943,400,000 Ordinary Shares represented by 9,434 American Depositary Shares, each ADS representing 100,000 Ordinary Shares. The company will not receive proceeds from resale by the selling shareholders; proceeds from any cash exercise of warrants would be received by the company.
This amendment updates information including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and selling shareholder details; no additional securities are being registered.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to its Form F-1 to update the prospectus and continue the resale registration for 1,701,800,000 ordinary shares represented by 17,018 American Depositary Shares issuable upon exercise of Series J warrants. The company states we will not receive any proceeds from resale by the selling shareholders; proceeds from any cash exercise of the Series J warrants would be received by the company. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026. The prospectus notes the Depositary Shares trade on NASDAQ under BDRX and quotes a last reported closing price of $0.6603 on March 26, 2026.
Biodexa Pharmaceuticals PLC, a UK-based early-stage biopharmaceutical company, files its annual report for the year ended December 31, 2025. The group reports net losses of £6.25 million in 2025, £5.73 million in 2024 and £7.08 million in 2023, leading to an accumulated deficit of £155.67 million as of December 31, 2025.
Cash and cash equivalents were £8.53 million at year-end 2025, and management states that additional financing will be required before the third quarter of 2026, creating material uncertainty and substantial doubt about the company’s ability to continue as a going concern. Biodexa has a $35.0 million equity line of credit, under which it has sold $8.92 million of shares, but there is no assurance this will be sufficient.
The company has no recurring revenue and depends on successfully developing and licensing its product candidates, such as eRapa, MTX240 and tolimidone, in a highly competitive and heavily regulated environment. Biodexa also highlights prior material weaknesses in internal controls, complex capital structure changes, extensive shareholder approvals for new shares and significant clinical, regulatory, reimbursement and collaboration risks typical of small biotechnology issuers.
Biodexa Pharmaceuticals reported a 2025 net loss of £6.38 million, with cash and cash equivalents of £8.53 million at year-end and a net cash inflow of £6.87 million driven by £13.04 million of financing inflows.
Research and development spending fell 27% to £3.96 million as MTX110 was removed from the pipeline, while administrative costs rose 27% to £4.84 million, mainly from professional and financing-related fees and foreign exchange movements. The company is advancing eRapa into a registrational Phase 3 FAP trial, supporting a fully enrolled Phase 2 NMIBC study, progressing a Phase 2a T1D study for tolimidone, and has in-licensed MTX240 for GIST.
Management and auditors highlight a material uncertainty around going concern, as forecasts show additional funding will be required in Q3 2026 despite access to a $35.0 million equity line of credit, of which $26.08 million remained undrawn at 31 December 2025.
Biodexa Pharmaceuticals Plc director Stephen Barry Parker filed an initial statement of ownership showing holdings of a stock option over 576 American Depositary Shares. The option has an exercise price of $475.0000 per ADS and expires on January 23, 2034.
The shares underlying this option vest over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to his continued service. Each American Depositary Share represents 100,000 ordinary shares of Biodexa.
Biodexa Pharmaceuticals is changing the ratio of its American Depositary Receipts to consolidate ADRs and support compliance with Nasdaq listing rules. Each ADR will shift from representing 100,000 ordinary shares to representing 500,000 ordinary shares, with the change expected to take effect on or about April 6, 2026.
ADR holders must surrender their existing ADRs and will receive one new ADR for every five old ADRs. No fractional ADRs will be issued; any aggregated fractions will be sold and the net cash distributed to entitled holders. This operates like a one-for-five reverse ADR split and does not affect the underlying ordinary shares. The company states the change is intended to help its ADR price meet Nasdaq’s $1.00 minimum bid requirement but gives no assurance this objective will be achieved.
Biodexa Pharmaceuticals Plc director Ann Louise Merchant reported an initial holding of a stock option over 288 American Depositary Shares, with an exercise price of $475.00 per ADS and an expiration date of January 23, 2034. The option vests over four years, starting with 25% after one year and 6.25% every three months thereafter, so long as she continues in service.
Biodexa Pharmaceuticals Plc Chief Executive Officer Stephen Anthony Stamp filed an initial Form 3 reporting his beneficial ownership of stock options. He holds options to buy 859 American Depositary Shares at an exercise price of $327.5000 per ADS expiring in 2034, and options over 1,500, 25,000 and 15,000 Ordinary Shares at exercise prices of $28.0500, $7.4100 and $5.4000 per share, with expirations between 2029 and 2031. The filing lists existing option awards and does not show any new purchases or sales.
Biodexa Pharmaceuticals director Simon de Vries filed an initial ownership report showing a stock option holding. The option covers 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The underlying shares vest over four years, with 25% vesting after one year and the remainder vesting quarterly, subject to continued service.